NasdaqGS:BMRNBiotechs
Did New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?
Earlier in June 2026, BioMarin Pharmaceutical reported new data at ENDO 2026 showing sustained growth benefits and a favorable safety profile for VOXZOGO in hypochondroplasia, alongside encouraging Phase 1 results for long-acting BMN 333 in achondroplasia that supported weekly dosing.
The updates not only underline VOXZOGO’s potential to reach thousands of additional rare-disease patients but also highlight BMN 333 as a possible next-generation option in achondroplasia care.
We’ll now...